Bacterial Infectious Diseases Therapeutics Market - 2021-2031

November 2025 | 207 pages | ID: B3270891118AEN
DataM Intelligence

Abstracts

The Bacterial Infectious Diseases Therapeutics Market was valued at USD 75.8 billion in 2021 and is anticipated to reach by 2031, at a CAGR of 0.082 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Bacterial Infectious Diseases Therapeutics Market.

This report delivers a comprehensive overview of the Bacterial Infectious Diseases Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bacterial Infectious Diseases Therapeutics Market. The Bacterial Infectious Diseases Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.

Bacterial Infectious Diseases Therapeutics Market Scope:

Key Players

• Novartis AG
• GlaxoSmithkline plc
• Pfizer Inc.
• Merck & Co., Inc.
• Sanofi
• Allergan
• Bayer AG
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Baxter
• Eli Lilly and Company
• Johnson and Johnson
• Insmed, Inc.
• Otsuka Pharmaceuticals Co., Ltd.
• Roche Holding AG
• Forest Laboratories, Inc.
• Teva Pharmaceuticals Industries Ltd.(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Bacterial Infectious Diseases Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bacterial Infectious Diseases Therapeutics Market. The Bacterial Infectious Diseases Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Disease Type
3.2. Market Snippet by Therapeutics
3.3. Market Snippet by Route of Administration
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Growing Older Population
    4.1.1.2. Increasing Prevalence of Bacterial Infectious Diseases
    4.1.1.3. XX
  4.1.2. Restraints
    4.1.2.1. Adverse Effects of Therapeutics
    4.1.2.2. Genetic Mutations
    4.1.2.3. XX
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY DISEASE TYPE

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
7.3. Market Attractiveness Index, By Disease Type Segment
  7.3.1. Bacterial Skin Infections*
    7.3.1.1. Introduction
    7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  7.3.2. Foodborne Bacterial Infections
  7.3.3. Sexually Transmitted Bacterial Infections
  7.3.4. Others

8. BY THERAPEUTICS

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
8.3. Market Attractiveness Index, By Therapeutics Segment
  8.3.1. Beta-Lactam*
    8.3.1.1. Introduction
    8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  8.3.2. Quinolones
  8.3.3. Macrolides
  8.3.4. Tetracyclines
  8.3.5. Sulfonamide
  8.3.6. Others

9. BY ROUTE OF ADMINISTRATION

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.3. Market Attractiveness Index, By Route of Administration Segment
  9.3.1. Oral*
    9.3.1.1. Introduction
    9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  9.3.2. Topical
  9.3.3. Parenteral
  9.3.4. Others

10. BY DISTRIBUTION CHANNEL

10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3. Market Attractiveness Index, By Distribution Channel Segment
  10.3.1. Hospitals Pharmacies*
    10.3.1.1. Introduction
    10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  10.3.2. Retail Pharmacies
  10.3.3. Online Pharmacies
  10.3.4. Others

11. BY REGION

11.1. Introduction
11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. U.S.
    11.4.7.2. Canada
    11.4.7.3. Mexico
11.5. Europe
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. Germany
    11.5.7.2. U.K.
    11.5.7.3. France
    11.5.7.4. Italy
    11.5.7.5. Spain
    11.5.7.6. Rest of Europe
11.6. South America
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.6.7.1. Brazil
    11.6.7.2. Argentina
    11.6.7.3. Rest of South America
11.7. Asia Pacific
  11.7.1. Introduction
  11.7.2. Key Region-Specific Dynamics
  11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    11.7.7.1. China
    11.7.7.2. India
    11.7.7.3. Japan
    11.7.7.4. Australia
    11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
  11.8.1. Introduction
  11.8.2. Key Region-Specific Dynamics
  11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Novartis AG*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. GlaxoSmithkline plc
13.3. Pfizer Inc.
13.4. Merck & Co., Inc.
13.5. Sanofi
13.6. Allergan
13.7. Bayer AG
13.8. AstraZeneca Plc
13.9. Bristol-Myers Squibb Company
13.10. Takeda Pharmaceutical Company Limited
13.11. Baxter
13.12. Eli Lilly and Company
13.13. Johnson and Johnson
13.14. Insmed, Inc.
13.15. Otsuka Pharmaceuticals Co., Ltd.
13.16. Roche Holding AG
13.17. Forest Laboratories, Inc.
13.18. Teva Pharmaceuticals Industries Ltd.(LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us